The United Kingdom’s National Health Service (NHS) may soon see relief from a critical shortage of bone cement, a vital component in hip and knee replacement surgeries, thanks to a swift decision by medical device company Biocomposites. The company announced on February 24, 2026, that it is immediately launching its Synicem bone cement products in the UK, accelerating a planned rollout to address the current supply crisis. This move comes after the successful introduction of Synicem antibiotic-loaded preformed spacers in the UK last year.
Bone cement, a material used to secure prostheses during joint replacement procedures, has faced significant supply chain disruptions, leading to concerns about potential delays in essential surgeries. According to Biocomposites CEO Michael Harris, the NHS is experiencing an “acute bone cement supply crisis” that threatens to postpone thousands of orthopaedic operations. The company, one of a limited number globally capable of large-scale bone cement manufacturing, is responding by not only expediting the launch of its Synicem products but also by doubling its manufacturing capacity, specifically to meet UK demand.
Synicem: A Quarter-Century of Development and a Range of Options
The Synicem bone cement line boasts over 25 years of manufacturing history under its parent company, Synimed, a subsidiary of Biocomposites. The product range is designed to provide secure and stable fixation between the prosthesis and bone, even in cases involving irregular surfaces. Synicem is available in both high and low viscosity formulations and can be supplied with or without the antibiotic gentamicin. This flexibility allows surgeons to tailor the cement to the specific needs of each patient and procedure.
The inclusion of gentamicin in certain Synicem formulations is particularly important for revision surgeries and for patients at higher risk of infection. Gentamicin is effective against a range of bacteria, including gentamicin-sensitive strains, and can provide an added layer of protection for patients with compromised immune systems. The availability of antibiotic-loaded options is a crucial factor in minimizing the risk of post-operative infections, a significant concern in joint replacement surgery.
Addressing the NHS Supply Crisis
The decision to accelerate the launch of Synicem in the UK was a direct response to the escalating bone cement shortage within the NHS. The NHS, responsible for providing healthcare to over 67 million people in the UK, relies heavily on a consistent supply of medical devices like bone cement to maintain its surgical capacity. Disruptions to this supply chain can have a cascading effect, leading to longer waiting lists and potentially impacting patient outcomes.
Harris emphasized Biocomposites’ commitment to supporting the NHS during this challenging time. “We at Biocomposites… want to do everything we can to help, so patients do not have to wait any longer than absolutely necessary for their vital operations,” he stated. The company’s rapid response demonstrates a proactive approach to addressing a critical healthcare demand and underscores the importance of resilient supply chains in the medical device industry.
Beyond Bone Cement: Biocomposites’ Expanding Portfolio
The launch of Synicem bone cements builds on Biocomposites’ recent expansion of its product offerings in the UK. In September 2024, the company commenced distribution of its NanoBone product range in the UK, further strengthening its presence in the orthopaedic market. Medical Device Network reported on this expansion, highlighting NanoBone’s potential to improve bone regeneration and healing.
NanoBone is a synthetic bone graft material designed to promote faster and more complete bone healing. It is used in a variety of orthopaedic procedures, including fracture repair and spinal fusion. The addition of NanoBone to Biocomposites’ UK portfolio demonstrates the company’s commitment to innovation and its focus on providing surgeons with a comprehensive range of advanced bone regeneration solutions.
What is Bone Cement and Why is it Important?
Bone cement, typically polymethylmethacrylate (PMMA), is a material used to fix orthopaedic implants, such as hip and knee replacements, to the bone. It acts as an interface between the implant and the bone, providing immediate stability and allowing for weight-bearing soon after surgery. The cement fills gaps and irregularities on the bone surface, creating a strong and durable bond. Still, the manufacturing process and supply chain for bone cement are complex, making it vulnerable to disruptions.
The importance of a reliable supply of bone cement cannot be overstated. Joint replacement surgery is a common and highly effective procedure for relieving pain and improving mobility in patients with arthritis and other joint conditions. Delays in these surgeries can significantly impact patients’ quality of life, leading to chronic pain, disability, and reduced independence.
Regulatory Approvals and Conformité Européenne (CE) Marking
Biocomposites confirmed that the Synicem bone cements hold Conformité Européenne (CE) marking and have received full regulatory approval for use in the UK. CE marking is a mandatory conformity marking for certain products sold within the European Economic Area (EEA). It indicates that the product meets relevant European health, safety, and environmental protection standards. This assurance of regulatory compliance is crucial for ensuring patient safety and product efficacy.
The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK’s regulatory body responsible for ensuring the safety, quality, and effectiveness of medicines and medical devices. Biocomposites’ adherence to MHRA regulations demonstrates its commitment to maintaining high standards of quality control and patient safety.
Looking Ahead: Continued Supply and Manufacturing Expansion
Biocomposites’ commitment to addressing the bone cement supply crisis extends beyond the immediate launch of Synicem. The company is actively doubling its manufacturing capacity to meet the increased demand, particularly from the UK. This investment in production capabilities will help to ensure a more stable and reliable supply of bone cement for the NHS and other healthcare providers in the region.
The company has not yet specified a timeline for the completion of the manufacturing expansion, but has indicated that it is prioritizing this initiative to minimize further disruptions to surgical schedules. Ongoing monitoring of the supply chain and proactive measures to mitigate potential risks will be essential to maintaining a consistent flow of bone cement to meet the needs of patients and healthcare professionals.
The situation remains fluid, and further updates regarding the bone cement supply in the UK will be closely monitored. Biocomposites’ actions represent a significant step towards alleviating the current crisis and ensuring that patients continue to have access to the essential orthopaedic surgeries they need.
What are your thoughts on the bone cement supply crisis and Biocomposites’ response? Share your comments below, and please share this article with your network.